[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dry-eye\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dry-eye":25},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,62,0,25,[9,39,63,90,116,140,167,188,213,238,265,288,312,336,354,385,406,426,453,471,491,511,531,553,575],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100641369","long-term-effects-of-acoltremon-vs-control-in-dry-eye-disease-100641369",false,"NCT07659626","Long-term Effects of Acoltremon vs. Control in Dry Eye Disease","A Randomized, Investigator-masked, Longitudinal Study Evaluating Long-term Changes in Symptoms and Tear Production of Acoltremon Ophthalmic Solution 0.003% Compared to Control in Subjects With Dry Eye Disease","Inclusion Criteria:\n\n1. Male or female, 18 years of age or older at the Screening visit.\n2. Have a previous history of DED, clinician diagnosed, or patient reported, within the previous 6 months prior to the Screening visit.\n3. Have used, and\u002For desired to use artificial tears for DED symptoms within 2 months prior to the Screening visit.\n4. Both of the following signs of DED in the same eye:\n\n   1. Total corneal fluorescein staining score of \\>= 2 and \\\u003C= 10 based on the NEI grading scheme, with no one region scoring \\> 3 in at least 1 eye.\n   2. Unanesthetized Schirmer test score \\>= 2 and \\\u003C 10 mm\u002F5 min in at least 1 eye.\n   3. If both eyes qualify, the eye with the lower baseline Schirmer score will be the study eye (If the Schirmer score is the same, the right eye will be the study eye).\n5. Symptomatic defined as an ODS-VAS score of \\>=40.\n6. Corrected visual acuity equal to or better than logMar +0.7 (Snellen equivalent equal to or better than 20\u002F100), as assessed by Early Treatment of Diabetic Retinopathy Study (ETDRS) scale in both eyes.\n7. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.\n8. Written informed consent from the subject has been obtained prior to any study related procedures.\n9. Able, as assessed by the investigator, and willing to follow study instructions and likely to complete all required study visits.\n\nExclusion Criteria:\n\n1. History or presence of any ocular disorder or condition (other than DED) in either eye that would, in the opinion of the investigator, interfere with the interpretation of the study results or subject safety.\n2. Diagnosis of recurrent, ongoing, or active ocular infection.\n3. History of ocular surgery within 1 year prior to the Screening visit.\n4. Have had a corneal transplant in either or both eyes.\n5. Use of contact lenses within 2 hours of any study visit.\n6. Use of lid heating therapy or Meibomian gland probing\u002Ftherapeutic expression within 1 year prior to the Screening visit.\n7. Use of artificial tears within 24 hours of Screening visit.\n8. Use of any topical ocular anti-inflammatory medication or dry eye pharmaceuticals within 30 days prior to the Screening visit.\n9. Use of any topical ocular glaucoma medication within 30 days prior to the Screening visit.\n10. Change in use of any other topical ocular medication within 14 days prior to the Screening visit.\n11. Use of medications for the treatment of severe DED and\u002For Meibomian gland disease within 30 days prior to the Screening visit.\n12. Initiation, discontinuation, or change in dose of a systemic medication known to cause ocular drying less than 14 days prior to the Screening visit.\n13. Use of a systemic corticosteroid less than 30 days prior to the Screening visit.\n14. Use of a systemic immunomodulator within 30 days prior to the Screening visit.\n15. Use of an investigational product or device within 30 days prior to the Screening visit.\n16. At the Screening visit, have uncontrolled or severe systemic allergy, rhinitis or sinusitis.\n17. History or presence of significant systemic disease.\n18. Known allergies or sensitivity to the study interventions or study diagnostic agents.\n19. Women of childbearing potential who are not using a medically acceptable form of birth control.\n20. The subject has a condition or is in a situation that, in the Investigator's opinion, may put the subject at significant risk.","ALL","18 Years",{"count":20,"type":21},60,"ESTIMATED","OBSERVATIONAL","This is a prospective, longitudinal, single-center study designed to evaluate the long-term changes in symptoms and tear production in subjects with dry eye disease. The study is randomized and investigator-masked, with subjects assigned to either the TRYPTYR (Acoltremon ophthalmic solution 0.003%) arm or the control arm (Refresh Classic Preservative-free). The study will be conducted at a single site, with subjects undergoing assessments at baseline and at months 1, 3, 6, 9, and 12.",[25],"Dry Eye","RECRUITING","2026-08-19",{"date":29,"type":30},"2026-08-20","ACTUAL",{"date":32,"type":30},"2026-08-18",{"date":34,"type":21},"2029-07-20",{"name":36,"class":37},"The Eye Care Institute","OTHER",1,{"id":40,"slug":41,"hasResults":12,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":12,"sex":17,"minAge":46,"maxAge":47,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":55,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":38},"100543766","phase-3-study-of-5-vvn001-ophthalmic-solution-in-dry-eye-disease-100543766","NCT06360133","Study of 5% VVN001 Ophthalmic Solution in Dry Eye Disease","A Phase 3, Randomized, Double-Masked, Vehicle-controlled, Multi-center Study Evaluating the Safety and Efficacy of 5% VVN001 in Chinese Subjects With Dry Eye Disease","Inclusion Criteria:\n\n* Provided written informed consent prior to any study-related procedures.\n* Are between 30 and 80 years of age.\n* Have a history of dry eye disease in both eyes.\n* Have been using artificial tears within 30 days of the screening visit\n* Have an Eye dryness score ≥50 (0-100 point VAS)\n* Have ongoing dry eye disease in the same eye or both eyes, as defined by all of the following criteria in the study eye and the same eye at Visit 1 and Visit 2: 1) total CFS (tCFS) score ≥6; 2) any subregion CS score ≥2.5; 3) Schirmer score (without anesthesia) ≥1 and ≤7 mm\u002F5 min.\n* Have a BCVA in the study eye of ≥4.3 (Standard for Logarithmic Visual Acuity Charts, 5-mark record).\n\nExclusion Criteria:\n\n* Have a known hypersensitivity or contraindication to the IP or components of IP.\n* Have history of uncontrolled glaucoma, IOP over 21 mmHg in either eye at the screening visit or are being treated with eye drops for glaucoma in the study eye. Or the subject has had laser or surgery for glaucoma in the study eye within 90 days of the study.\n* Woman of childbearing potential (WOCP) who are pregnant, lactating, or preparing for pregnant.","30 Years","80 Years",{"count":49,"type":21},700,"INTERVENTIONAL",[52],"PHASE3","This is a Phase 3, randomized, double-Masked, vehicle-controlled, multi-center study designed to evaluate the safety and efficacy of 5% VVN001 Ophthalmic Solution versus vehicle in Chinese subjects with dry eye disease.",[25],{"date":29,"type":30},{"date":57,"type":30},"2024-04-01",{"date":59,"type":21},"2027-04-30",{"name":61,"class":62},"VivaVision Biotech, Inc","INDUSTRY",{"id":64,"slug":65,"hasResults":12,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":12,"sex":17,"minAge":46,"maxAge":70,"enrollmentInfo":71,"targetDuration":4,"studyType":50,"phases":73,"briefSummary":74,"conditions":75,"keywords":76,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":89},"100649860","phase-3-phase-iii-study-of-ot202-in-treating-moderate-to-severe-dry-eye-100649860","NCT07740564","Phase III Study of OT202 in Treating Moderate to Severe Dry Eye","A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of OT202 Eye Drops in the Treatment of Moderate to Severe Dry Eye","Inclusion Criteria:\n\n1. 30 to 75 years of age (inclusive) at the time of signing the ICF, either sex or ethnic group.\n2. With history of dry eye for at least 6 months prior to screening, and history of use or willingness to use eye drops for the treatment of dry eye within 6 months prior to screening.\n3. Binocular BCVA ≥ 0.25 decimals (standard logarithmic visual acuity chart) at Screening and Baseline.\n4. At least one eye (the same eye) meets all the following criteria at screening and baseline:\n\n   * 5 ≤ TCSS ≤ 15, with individual corneal region staining ≤ 3\n   * Eye dryness score (EDS) ≥ 40 points in VAS\n   * TFBUT ≤ 5 seconds\n   * 1 mm\u002F5 min ≤ Schirmer I test (without surface anesthesia) ≤ 10 mm\u002F5 min\n5. Must be able to understand and sign the ICF approved by Independent Ethics Committee (EC).\n6. Willing and able to conduct protocol-required study visits, follow study guidelines, and take study drug as instructed.\n\nExclusion Criteria:\n\n1. Patients who have previously participated in a Phase I or Phase II clinical study of OT202\n2. With contraindication or hypersensitivity to the study drug (OT202 and excipients) or diagnostic reagents (fluorescein sodium, lissamine green, etc.).\n3. During the screening period and baseline period, any eye with ocular active inflammation or structural abnormalities that may affect the trial assessment, including but not limited to trichiasis, blepharospasm, blepharitis, meibomitis, severe meibomian gland dysfunction(diagnosed according to the Expert Consensus on the Diagnosis and Treatment of Meibomian Gland Dysfunction in China (2023)), bulbar conjunctival laxity, keratitis, recurrent corneal erosion, allergic conjunctivitis, iritis, anterior chamber inflammation, known retinal detachment, diabetic retinopathy, or history of any progressive retinal disease.\n4. With history of possible or confirmed ocular infection (bacterial, viral, or fungal) or ocular herpes (simple or zoster) in either eye, as determined by the patient's medical history and\u002For at the screening and baseline examinations.\n5. Those with intraocular pressure (non-contact tonometry) greater than 21 mmHg or less than 8 mmHg or diagnosed with glaucoma at screening and baseline, or those with ocular hypertension who underwent intraocular pressure reduction therapy, and those with a history or suspicion of glaucoma.\n6. Those with any systemic disease are expected to potentially affect the study results. It includes but is not limited to Sjögren syndrome, Stevens-Johnson syndrome, rheumatoid arthritis, graft versus host disease, systemic lupus erythematosus, scleroderma, sarcoidosis, herpes, acne, rosacea, etc.\n7. Those who cannot stop using any ocular medication or treatment during the clinical trial.\n8. Those with recent clinically relevant history (e.g., hepatic, renal impairment) within 6 months prior to screening or current severe, unstable, or uncontrolled cardiovascular, pulmonary, hepatic, renal, autoimmune, and other relevant systemic diseases (e.g., severe chronic obstructive pulmonary disease, arrhythmia, significant heart failure, uncontrolled hypertension, type 2 diabetes mellitus), as assessed by the investigator.\n9. Those on a chronic, systemic medication regimen used for less than 1 month at screening and baseline or with dose changed within 1 month (including initiation of new medication and discontinuation).\n10. Those who have used any prohibited medications (topical ocular, systemic, and\u002For injectable medications) during the specified period prior to screening. These medications are also prohibited during the study. However, if a subject has a prohibited medication at screening, it needs to be stopped and washed out according to the washout period specified below, which can be included in the wash-out period. The minimum reasonable washout period for prohibited medications is as follows:\n\n    * Systemic and local immunosuppressant and immunotherapy (such as cyclosporine eye drops, tacrolimus eye drops, etc.): 60 days;\n    * Corticosteroids (any route): 14 days;\n    * Systemic or ocular topical mast cell stabilizers, antihistamines, antihistamines\u002Fmast cell stabilizer combination, vasoconstrictors, monoamine oxidase inhibitors: 7 days;\n    * Other topical ophthalmic preparations (including artificial tears): 3 days;\n    * Medications known to cause ocular dryness (e.g., anticholinergics, serotonin reuptake inhibitors, beta-blockers, diuretics, etc.): 14 days.\n\n    Note: Non-periocular, low-potency, over-the-counter corticosteroid topical skin creams are allowed for use in the study (e.g., hydrocortisone butyrate cream\u002Fointment).\n11. Those who wore corneal contact lenses within 7 days prior to screening or required them during the study.\n12. Those who underwent meibomian gland massage or moist chamber therapy within 7 days prior to screening, or non-drug therapies for dry eye such as intense pulsed light therapy, thermal pulsation therapy, etc., within the previous 6 months before screening.\n13. Those who previously underwent dry eye surgery such as tear duct embolization (current tear duct embolization status or punctal plug use in the past 6 months) or amniotic membrane transplantation.\n14. Those who underwent ocular surface surgery (e.g., LASIK excimer laser in situ keratomileusis) within 12 months prior to screening or intraocular surgery within 6 months prior to screening in either eye, as determined by the subject's medical history and\u002For examination, or anticipated ocular surgery during the study.\n15. Those who use other investigational products or devices within 3 months prior to screening or concurrently during the study.\n16. Non-compliance with drug administration (\\\u003C 80% or \\> 120%) during the introduction period.\n17. Females of childbearing potential who are currently pregnant, or have a positive pregnancy test result, or plan to get pregnant during the study, or are currently breastfeeding, or do not agree to use appropriate contraception methods to avoid pregnancy during the study period up to 1 month after the last dose of study drug.\n18. Males who do not agree to use one or more acceptable effective contraception methods during the study period up to 1 month after the last dose of study drug.\n19. Any condition or situation that, in the opinion of the investigator, may pose a safety risk to the subject in the trial or may interfere with the conduct of the study, or the investigator believes that the subject may not be able to complete or comply with the requirements of the study (due to administrative reasons or otherwise).","75 Years",{"count":72,"type":21},842,[52],"This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical trial, enrolling 842 subjects with moderate to severe dry eye, who will be randomized at a 1:1 ratio to receive either 1% OT202 ophthalmic solution or vehicle control. The trial consists of screening, run-in, 8-week double-blind treatment period, and three long-term safety follow-up cohorts (10 weeks, 28 weeks, and 54 weeks), including 342 subjects for the 10-week follow-up, 350 subjects for the 28-week follow-up, and 150 subjects for the 54-week follow-up. Unblinding will be performed after the completion of double-blind treatment for all subjects, who will then receive open-label 1% OT202 ophthalmic solution uniformly. The co-primary efficacy endpoints are the change from baseline in Total Corneal Fluorescein Staining Score (TCSS) and Visual Analog Scale-Eye Dryness Score (VAS-EDS) at Day 56. Pharmacokinetic assessments will be conducted in 60 of the subjects assigned to the 54-weeks long-term safety follow-up. An interim futility analysis will be performed once approximately 30% of subjects complete the treatment period. Analysis of covariance (ANCOVA) will be utilized for efficacy statistical analyses. The primary objective is to evaluate the efficacy and safety of OT202 ophthalmic solution in the treatment of moderate to severe dry eye.",[25],[77,78],"Moderate dry eye","Severe dry eye","NOT_YET_RECRUITING","2026-07-28",{"date":82,"type":30},"2026-07-31",{"date":84,"type":21},"2026-08",{"date":86,"type":21},"2029-05",{"name":88,"class":62},"Ocumension Therapeutics (Suzhou) Co., Ltd",49,{"id":91,"slug":92,"hasResults":12,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":97,"sex":17,"minAge":18,"maxAge":98,"enrollmentInfo":99,"targetDuration":4,"studyType":50,"phases":101,"briefSummary":103,"conditions":104,"keywords":105,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":112,"leadSponsor":114,"locationsCount":38},"100647146","treating-contact-lens-discomfort-with-varenicline-solution-nasal-spray-003mg-100647146","NCT07705893","Treating Contact Lens Discomfort With Varenicline Solution Nasal Spray 0.03mg","A Clinical Evaluation of Treating Contact Lens Discomfort With Varenicline Solution Nasal Spray 0.03mg","Inclusion Criteria:\n\n* Adult male and female subjects of any race or ethnicity who are ≥18 years of age.\n* Best corrected CL visual acuity of 0.3 Logarithm of the Minimum Angle of Resolution (logMAR) or better in both eyes (Snellen equivalent 20\u002F40).\n* Soft 1-day silicone hydrogel CL wearer (daily disposable only)\n* Contact Lens Dry Eye Questionnaire (CLDEQ)-8 scores (CLDEQ-8 scores ≥ 12).16\n* A VAS score of ≥40 for Eye Dryness and End of Day Contact Lens Discomfort;18, 19\n* A corneal fluorescein staining on the original NEI scale of ≥3.\n* Habitually wears soft CLs for a minimum of 5 days per week for 6 hours per day during the month prior to enrollment.20\n* Willing to maintain habitual CL wear routine for the 3 months duration of the study.20\n* Willing to only use Tyrvaya nasal spray prescription dry eye treatment for the 3 months duration of the study.\n* Willing to not use any lipid containing artificial tear (AT) for the 3 months duration of the study.\n* Willing to only use non-lipid containing preservative free artificial tear for the 3 months duration of the study if needed, but no more than 4 times per day; also must agree to record frequency of daily AT use if applicable.\n* Willing to record daily time for CL application, removal, and Tyrvaya applications.\n* Habitual CLs have an acceptable fit (good centration, movement, and coverage\n\nExclusion Criteria:\n\n* Any history of Tyrvaya use within six months of enrollment\n* Are currently an overnight CL wearer.\n* Are currently wearing rigid gas permeable CLs, scleral CL, hybrid CLs, or reusable soft CLs.\n* Have known systemic health conditions that are known to alter tear film physiology (e.g., primary and secondary Sjögren's syndrome).\n* Have a history of ocular surgery within the past 12 months.\n* Have a history of viral eye disease.\n* Have a history of severe ocular trauma, active ocular infection or inflammation.\n* Have ever used using isotretinoin-derivates (e.g., Accutane).\n* Are currently taking ocular medications or plan to during the study (e.g., DED, glaucoma, etc).\n* Subjects with meibomian gland blockage or significant atrophy (e.g., severe MGD). Currently having \\>50% blockage of Meibomian glands in more than two eyelids\n* Having blepharitis and\u002For demodex blepharitis \\> grade 1\n* Have had a physical meibomian gland dysfunction treatment withing three months of enrollment (iLux, Lipiflow, Radio Frequency and IPL with manual expressions, microblepharoexfoliation etc.).\n* Have used a prescription DED or ocular surface disease medication in the last 1 month.\n* Have a condition or in a situation, which in the examiner's opinion, may put the subject at significant risk, may confound the study results, or may significantly interfere with their participation.\n* Are pregnant or breast feeding or plan to get pregnant.\n* Are a student, employee, or relative of the study team.",true,"99 Years",{"count":100,"type":21},50,[102],"NA","The objective of this study is to evaluate whether twice-daily use of Tyrvaya improves contact lens comfort in contact lens wearers.",[25],[106,25,107,108],"Tyrvaya","Contact Lens","Symptoms",{"date":110,"type":30},"2026-07-30",{"date":80,"type":30},{"date":113,"type":21},"2027-03",{"name":115,"class":37},"Ocular Aesthetics, LLC dba Ocular Clinical Trials",{"id":117,"slug":118,"hasResults":12,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":4,"eligibilityCriteria":122,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":123,"targetDuration":4,"studyType":50,"phases":125,"briefSummary":127,"conditions":128,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":38},"100624710","phase-2-autologous-serum-tears-with-hyaluronate-vs-balanced-salt-solution-for-moderate-to-severe-dry-eye-100624710","NCT07413172","Autologous Serum Tears With Hyaluronate vs Balanced Salt Solution for Moderate-to-Severe Dry Eye","The Effect of Autologous Serum Tears Diluted to 50% With 0.2% Sodium Hyaluronate-Containing Preservative-Free Artificial Tears Versus Autologous Serum Tears Diluted to 50% With Balanced Salt Solution in Patients With Moderate-to-Severe Dry Eye Disease: A Prospective, Double-Blind, Randomized, Controlled, Contralateral-Eye Study","Inclusion Criteria:\n\n* Age ≥ 18 years old\n\n  * Formal diagnosis of one of the following conditions associated with aqueous-deficient dry eye disease: Sjögren's syndrome (primary or secondary), Mucous membrane pemphigoid, Graft-versus-host disease, Stevens-Johnson syndrome, Post-radiation lacrimal gland aqueous deficiency, or Neurotrophic keratitis\n  * Moderate-to-severe Dry Eye Disease (DED) symptoms for at least 6 months prior to study enrollment.\n  * OSDI score ≥ 25 and\u002For and OSDI-6 score \\> 6 at the screening visit\n  * Presence of at least two of the following clinical signs in the same eye, at the screening visit: Anesthetized Schirmer's test score 7 ≤ mm at 5 minutes, Tear Break up Time (TBUT) ≤ 7 seconds, Corneal fluorescein staining score ≥ 4 (maximum 15) as assessed by the National Eye Institute (NEI) grading scale 25, or Conjunctival lissamine green staining ≥ 3 (maximum 18) as assessed by the NEI grading scale\n  * Desire to use autologous serum tears at least twice daily in the 2 weeks prior to screening visit.\n\nExclusion Criteria:\n\n* Age \\\u003C18 years old.\n\n  * Cognitive impairment or psychiatric condition that precludes informed consent or the ability to comply with study procedures.\n  * Any clinical condition identified at screening that, in the opinion of the treating physician, is clinically significant and would contraindicate safe participation in the study.\n  * Any condition or treatment known to affect the signs and symptoms of DED, including pregnancy, regular use of contact lenses, recent diagnosis of ocular allergy, infection, or inflammation, or recent ocular surgery within 6 months.\n  * Patients with stable ocular surface disease or neurotrophic keratitis secondary to prior ocular surgery, chronic glaucoma therapy, or eyelid abnormalities may be included.",{"count":124,"type":21},20,[126],"PHASE2","This study aims to find out whether adding sodium hyaluronate, a moisturizing ingredient commonly found in artificial tears, makes autologous serum eye drops more effective for treating moderate-to-severe dry eye disease. Each participant will use one version of the drops in one eye and the standard version in the other eye. The goal is to see if the new combination provides better relief, comfort, and eye surface healing compared to the traditional formulation.",[25,129,130],"Eye Diseases","Eyes Dry Chronic","2026-07-22",{"date":133,"type":30},"2026-07-24",{"date":135,"type":30},"2026-07-21",{"date":137,"type":21},"2028-07",{"name":139,"class":37},"University of Miami",{"id":141,"slug":142,"hasResults":12,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":4,"eligibilityCriteria":146,"healthyVolunteers":97,"sex":17,"minAge":18,"maxAge":147,"enrollmentInfo":148,"targetDuration":4,"studyType":50,"phases":150,"briefSummary":151,"conditions":152,"keywords":155,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":162,"completionDateStruct":163,"leadSponsor":165,"locationsCount":38},"100647168","a-study-of-full-spectrum-screen-lighting-for-reducing-screen-related-eye-fatigue-and-dry-eye-100647168","NCT07706231","A Study of Full-Spectrum Screen Lighting for Reducing Screen-Related Eye Fatigue and Dry Eye","A Randomized Controlled Trial of the Effects of Full-Spectrum Screen Bar Lighting on Visual Fatigue and Dry Eye After a Standardized Screen Task","Inclusion Criteria:\n\n1. Age 18 to 35 years, male or female.\n2. Average daily electronic screen exposure of at least 4 hours.\n3. Near visual acuity at 40 cm of 0.5 or better, and able to complete the study 1. tasks and measurements stably.\n4. Able and willing to provide written informed consent.\n\nExclusion Criteria:\n\n1. Presence of ocular inflammation or ocular disease.\n2. History of severe systemic disease, neurological disease, or psychiatric disorder.\n3. Pregnancy or lactation.\n4. Use of dry eye or visual fatigue treatments, or contact lens wear, within 1 month before the study.\n5. History of ocular surgery within the past 6 months.\n6. Daily use of lenses with blue-light blocking, photochromic, polarized, filtering, or similar optical functions.\n7. Professional background in ophthalmology or optical products.\n8. Intake of caffeine or other stimulants within 4 hours before the study.\n9. Best-corrected visual acuity (BCVA) less than 0.8.\n10. Anisometropia of 1.00 diopter or greater, or astigmatism of ±2.00 diopters or greater.\n11. Intraocular pressure (IOP) less than 5 mmHg or greater than 21 mmHg.\n12. Non-invasive tear breakup time (NIBUT) less than 5 seconds in either eye.\n13. Ocular Surface Disease Index (OSDI) score of 33 or greater.","35 Years",{"count":149,"type":21},112,[102],"This study will evaluate whether full-spectrum screen bar lighting can reduce eye fatigue and dry eye symptoms after a standardized screen task. Prolonged screen use is common in daily work and study and may cause blurred vision, eye soreness, dryness, headache, and reduced attention. Light environment may be one way to improve visual comfort during screen use, but more controlled clinical evidence is needed.\n\nIn this randomized, parallel-group controlled study, 112 healthy adult participants will be assigned to either a full-spectrum screen bar lighting group or a brightness-matched control group without screen bar lighting. Participants in both groups will complete an approximately 2-hour standardized screen task in a controlled laboratory environment. The study will compare changes before and after the task in objective and subjective measures of visual fatigue and dry eye, including critical flicker fusion frequency, visual fatigue questionnaire scores, eye movement and blinking parameters, pupil parameters, tear film-related measurements, and dry eye symptom scores. Safety and discomfort during the study will also be recorded.",[153,25,154],"Visual Fatigue","Computer Vision Syndrome",[156,25,157,158,159],"Visual fatigue","Computer vision syndrome","Critical flicker fusion frequency","Full-spectrum","2026-07-20",{"date":131,"type":30},{"date":160,"type":21},{"date":164,"type":21},"2026-12-31",{"name":166,"class":37},"Zhongshan Ophthalmic Center, Sun Yat-sen University",{"id":168,"slug":169,"hasResults":12,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":4,"eligibilityCriteria":173,"healthyVolunteers":97,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":174,"targetDuration":4,"studyType":50,"phases":175,"briefSummary":177,"conditions":178,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":38},"100604865","phase-4-efficacy-of-kera-sol-tears-on-signs-and-symptoms-of-surgical-temporary-ocular-discomfort-syndrome-stods-in-subjects-following-lasik-100604865","NCT07155070","Efficacy of Kera Sol Tears on Signs and Symptoms of Surgical Temporary Ocular Discomfort Syndrome (STODS) in Subjects Following LASIK","Kera Sol Post-LASIK: A Benefit Study","Inclusion Criteria:\n\n* Be willing and able to sign the informed consent form (ICF)\n* Be at least 18 years of age at the screening visit\n* Be undergoing LASIK treatment in both eyes\n* Be literate and able to complete questionnaires independently\n* Be able and willing to use the study drug and participate in all study assessments and visits\n* Have provided verbal and written informed consent\n\nExclusion Criteria:\n\n* Use of topical prescription dry eye medications such as lifitegrast, cyclosporine, loltilaner, etc.\n* Have a break in the integrity of the corneal epithelium such as a persistent corneal epithelial defect, or corneal ulcer.\n* Have presence of corneal pathology that may interfere with LASIK outcomes\n* Active infectious, ocular or systemic disease\n* Have a history of ocular inflammation or macular edema\n* Have had clinically significant active infectious keratitis in the past 3 months 7. -Have history of prior refractive surgery\n* Have placement of temporary punctal plugs in the past 1 month or current presence of permanent punctal plugs at time of screening\n* Patients with usual relative and absolute contraindications for LASIK surgery (Patients with severe dry eye, recurrent corneal erosion, uncontrolled Glaucoma, collagen vascular disorders, keratoconus or signs of keratoconus, uncontrolled Diabetes, Herpes)\n* Autoimmune or immunodeficiency diseases\n* Pregnant or nursing women\n* Patients with history of previous ocular surgery, , except for previous cataract surgery.",{"count":20,"type":21},[176],"PHASE4","Collecting data using Kera Sol tear usage during the initial two-week post-operative period after Laser-Assisted In Situ Keratomileusis (LASIK) has on the signs and symptoms of surgical temporary ocular discomfort syndrome (STODS)",[25],"2026-07-09",{"date":181,"type":30},"2026-07-13",{"date":183,"type":30},"2025-08-01",{"date":185,"type":21},"2027-02-01",{"name":187,"class":37},"Vance Thompson Vision",{"id":189,"slug":190,"hasResults":12,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":194,"eligibilityCriteria":195,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":196,"targetDuration":4,"studyType":50,"phases":198,"briefSummary":199,"conditions":200,"keywords":202,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":38},"100643673","study-of-proteomic-factors-in-patients-with-severe-dry-eye-syndrome-treated-with-autologous-serum-eye-drops-100643673","NCT07632534","Study of Proteomic Factors in Patients With Severe Dry Eye Syndrome Treated With Autologous Serum Eye Drops.","Study of Proteomic Factors in Patients With Severe Dry Eye Syndrome Treated With Autologous Serum Eye Drops. Single-center Study.","Prot-CSA","Inclusion Criteria:\n\n* Age over 18 years\n* Patients with severe dry eye with an Oxford score \\> 1\n* Patients with dry eye syndrome refractory to conventional treatments: tear substitutes, immunosuppressive eye drops or corticosteroids.\n* AS-naïve patients followed by an ophthalmologist at Saint-Etienne University Hospital\n* Patients affiliated to or entitled under a social security scheme\n* Patients who have received informed information about the study\n\nExclusion Criteria:\n\n* Severe ocular dryness due to a genetic disease\n* Patients not under the care of an ophthalmologist at Saint-Etienne University Hospital.\n* Patients not eligible for treatment with AS (pregnant women, anaemia, current infection, progressive disease, serological results contraindicating blood sampling).\n* Patients under protective measures",{"count":197,"type":21},68,[102],"Dry eye syndrome is a multifactorial pathology of the ocular surface. Epidemiological studies report a prevalence of 15% in adults aged between 50 and 95. Depending on the severity of the disease, different treatment strategies may be proposed. The use of autologous serum eye drops (AS) represents an interesting therapeutic alternative for the most severe forms of the disease, due to the serum's composition, which is similar to that of tears. The mechanism of action of AS is still controversial, but is probably multifactorial and seems to be based on growth factors, vitamin factors and anti-inflammatory factors. The clinical response of patients could be dependent on the protein composition of the eye drops. The investigators are aiming to highlight a difference in serum protein composition that could explain the differences in clinical response between patients treated with autologous serum eye drops and to identify the proteins that would be involved in a clinical response or non-response.",[201,25],"Dry Eye Syndrome (DES)",[203,204],"autologous serum eye drops","dry eye disease","2026-07-08",{"date":179,"type":30},{"date":208,"type":30},"2026-07-07",{"date":210,"type":21},"2028-12",{"name":212,"class":37},"Centre Hospitalier Universitaire de Saint Etienne",{"id":214,"slug":215,"hasResults":12,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":4,"eligibilityCriteria":219,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":220,"enrollmentInfo":221,"targetDuration":4,"studyType":50,"phases":223,"briefSummary":224,"conditions":225,"keywords":226,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":235,"locationsCount":237},"100645148","phase-4-perfluorohexyloctane-eye-drops-vs-sodium-hyaluronate-for-video-display-terminal-associated-dry-eye-100645148","NCT07679685","Perfluorohexyloctane Eye Drops vs. Sodium Hyaluronate for Video Display Terminal-Associated Dry Eye","A Prospective, Multicenter, Randomized Controlled Trial on the Efficacy and Safety of Perfluorohexyloctane Eye Drops Versus 0.1% Sodium Hyaluronate Eye Drops in the Treatment of Video Display Terminal-associated Dry Eye","Inclusion Criteria:\n\n1. Age 18-70 years (inclusive), male or female;\n2. Subject reports dry eye symptoms for at least 6 months;\n3. Diagnosis of mild to moderate dry eye according to the Chinese Dry Eye Expert Consensus (2020) criteria:\n\n   * Mild dry eye: fluorescein tear film break-up time (FBUT) ≥2 seconds, no significant ocular surface damage signs, corneal fluorescein staining score \\\u003C5;\n   * Moderate dry eye: FBUT ≥2 seconds AND corneal fluorescein staining dots \\\u003C30 or not exceeding 2 quadrants;\n4. Normal tear secretion: Schirmer I test ≥10 mm\u002F5 min;\n5. Daily electronic screen usage \\>6 hours;\n6. Electronic screen use for at least 5 days\u002Fweek, for more than 1 year;\n7. Understands and provides written informed consent.\n\nExclusion Criteria:\n\n1. Allergy or hypersensitivity to any component of the study drugs;\n2. Requires the use of artificial tears (other than study drug), secretagogues, ocular surface repair agents, anti-inflammatory\u002Fantibiotic eye drops, or other dry eye-related drugs (e.g., muscarinic receptor blockers for visual fatigue) during the study period;\n3. Presence of any of the following ocular or systemic conditions:\n\n   * Active ocular infection, ocular inflammation, or active ocular allergy;\n   * Conjunctivochalasis, nasolacrimal duct obstruction;\n   * Glaucoma or elevated intraocular pressure;\n   * Retinal disease or ocular tumor;\n   * Requirement to wear contact lenses during the study;\n   * Obstructive sleep apnea syndrome or sleep disorders;\n   * Planned or ongoing physical therapy (intense pulsed light, meibomian gland massage, warm compress, thermopulsation) within 2 weeks before enrollment through the end of study;\n4. Ocular surgery within 3 months prior to enrollment, incomplete recovery from previous ocular surgery, or planned ophthalmic surgery during the study period;\n5. Current smoker;\n6. Pregnant or breastfeeding women, or women planning to become pregnant during the study period;\n7. Uncontrolled systemic disease, or use of systemic medications (e.g., beta-blockers, benzodiazepines, corticosteroids, antihistamines, or other medications that may interfere with tear production);\n8. History of anxiety or depression;\n9. Any other condition that, in the judgment of the investigator, would make the subject unsuitable for participation.","70 Years",{"count":222,"type":21},159,[176],"This is a prospective, multicenter, open-label, randomized controlled trial designed to evaluate the efficacy and safety of perfluorohexyloctane (PFHO) eye drops (Hengqin®, Chengdu Shengdi Pharmaceutical Co., Ltd.) compared with 0.1% sodium hyaluronate eye drops in patients with video display terminal (VDT)-associated dry eye.\n\nParticipants aged 18-70 years with mild to moderate dry eye (confirmed by Chinese Dry Eye Expert Consensus 2020 criteria) who use video display terminal for more than 6 hours\u002Fday and at least 5 days\u002Fweek for more than 1 year will be enrolled. A total of 159 subjects will be randomized in a 2:1 ratio to the experimental group (PFHO eye drops, n=106) or control group (0.1% sodium hyaluronate eye drops, n=53), both administered 1 drop\u002Feye, 4 times daily (3-5 hour intervals), bilaterally, for 8 weeks.\n\nThe primary endpoint is the change from baseline in fluorescein tear film break-up time (FBUT) at Week 8. Secondary endpoints include FBUT changes at Weeks 2 and 4, standard patient evaluation of eye dryness（SPEED） questionnaire score changes, total corneal fluorescein staining (tCFS), partial blink rate (PBR), non-invasive tear film break-up time (NIBUT), lipid layer thickness (LLT), meibomian gland secretion quality score, and This is a prospective, multicenter, open-label, randomized controlled trial designed to evaluate the efficacy and safety of perfluorohexyloctane (PFHO) eye drops (Hengqin®, Chengdu Shengdi Pharmaceutical Co., Ltd.) compared with 0.1% sodium hyaluronate eye drops (Hialid®) in patients with video display terminal (VDT)-associated dry eye.\n\nParticipants aged 18-70 years with mild to moderate dry eye (confirmed by Chinese Dry Eye Expert Consensus 2020 criteria) who use electronic screens for more than 6 hours\u002Fday and at least 5 days\u002Fweek for more than 1 year will be enrolled. A total of 159 subjects will be randomized in a 2:1 ratio to the experimental group (PFHO eye drops, n=106) or control group (0.1% sodium hyaluronate eye drops, n=53), both administered 1 drop\u002Feye, 4 times daily (3-5 hour intervals), bilaterally, for 8 weeks.\n\nThe primary endpoint is the change from baseline in fluorescein tear film break-up time (FBUT) at Week 8. Secondary endpoints include FBUT changes at Weeks 2 and 4, SPEED questionnaire score changes, total corneal fluorescein staining (tCFS), partial blink rate (PBR), non-invasive tear film break-up time (NIBUT), lipid layer thickness (LLT), meibomian gland secretion quality score, and meibography score at Weeks 2, 4, and 8.",[25],[227,228],"Dry eye","video display terminal","2026-06-29",{"date":231,"type":30},"2026-07-01",{"date":233,"type":21},"2026-06-30",{"date":59,"type":21},{"name":236,"class":37},"Beijing Tongren Hospital",9,{"id":239,"slug":240,"hasResults":12,"nctId":241,"briefTitle":242,"officialTitle":243,"acronym":4,"eligibilityCriteria":244,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":245,"targetDuration":4,"studyType":50,"phases":247,"briefSummary":248,"conditions":249,"keywords":251,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":38},"100641136","effect-of-dry-eye-treatment-on-corneal-astigmatism-measurements-100641136","NCT07657858","Effect of Dry Eye Treatment on Corneal Astigmatism Measurements","Effect of Dry Eye and Ocular Surface Treatment on Agreement and Repeatability of Corneal Astigmatism Measurements Among Three Devices","Inclusion Criteria:\n\n* Patients with age-related cataract undergoing preoperative ocular examination.\n* Ability to complete ocular surface evaluation, including the Ocular Surface\n* Disease Index questionnaire, non-invasive tear film break-up time, tear meniscus height, Schirmer test, and ocular surface staining.\n* Ability to complete repeated corneal astigmatism measurements using IOLMaster 700, Pentacam AXL, and iTrace Prime.\n* Ability to maintain stable fixation during device measurements. Provision of written informed consent.\n\nExclusion Criteria:\n\n* Previous ocular surgery or ocular trauma.\n* Corneal degeneration, corneal dystrophy, or other corneal diseases that could affect corneal measurements.\n* Active corneal or conjunctival infection.\n* Uveitis.\n* Use of any topical eye drops within 24 hours before examination.\n* Use of antiglaucoma medications.\n* Contact lens wear within 1 month before examination.\n* Previous or ongoing treatment for dry eye disease.\n* Poor fixation during device measurements.\n* Poor-quality measurements from any study device",{"count":246,"type":21},400,[102],"This prospective single-center study evaluates the effect of dry eye disease and short-term ocular surface treatment on the agreement and repeatability of corneal astigmatism measurements in patients with age-related cataract. Participants undergoing preoperative cataract evaluation are classified into a control group or a dry eye disease group according to ocular surface symptoms and objective tear film findings.\n\nAll participants undergo ocular surface assessment and repeated corneal measurements using three commonly used devices: IOLMaster 700, Pentacam AXL, and iTrace Prime. Measurements include keratometric corneal astigmatism, total corneal astigmatism, and vector components of astigmatism. Patients with dry eye disease receive 0.3% sodium hyaluronate eye drops four times daily for 2 weeks, after which ocular surface assessment and device measurements are repeated.\n\nThe primary objective is to determine whether dry eye disease reduces interdevice agreement and test-retest repeatability of corneal astigmatism measurements, and whether short-term ocular surface treatment improves measurement stability. Interdevice agreement is assessed using Bland-Altman analysis, and repeatability is evaluated using within-subject standard deviation, test-retest repeatability, and intraclass correlation coefficient.",[25,250],"Cataract",[252,250,253,254,255],"Dry Eye Disease","Corneal Astigmatism","Ocular Surface",";Biometry","2026-06-15",{"date":258,"type":30},"2026-06-18",{"date":260,"type":30},"2026-01-01",{"date":262,"type":21},"2030-12-31",{"name":264,"class":37},"Jin Yang",{"id":266,"slug":267,"hasResults":12,"nctId":268,"briefTitle":269,"officialTitle":270,"acronym":271,"eligibilityCriteria":272,"healthyVolunteers":97,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":273,"targetDuration":4,"studyType":50,"phases":275,"briefSummary":276,"conditions":277,"keywords":4,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":283,"completionDateStruct":285,"leadSponsor":286,"locationsCount":4},"100585534","phase-3-phase-iii-study-of-topical-fibrinogen-depleted-human-platelet-lysate-compared-to-placebo-for-moderate-to-severe-dry-eye-100585534","NCT06903611","Phase III Study of Topical Fibrinogen-Depleted Human Platelet Lysate Compared to Placebo for Moderate to Severe Dry Eye","CAMOMILE-2: Phase III Randomized, Double-Masked, Safety and Efficacy Study of Topical Fibrinogen-Depleted Human Platelet Lysate Compared to Vehicle Control for the Treatment of Moderate to Severe Dry Eye","CAMOMILE-2","Inclusion Criteria:\n\n1. Male or female subjects who at the time of consent are 18 years of age or older, if participating at a study site located in the U.S.\n2. Having a self-reported history of dry eye disease within the past 6 months.\n3. NEI Corneal Fluorescein Staining Score in at least one eye at screening and at Day 0 (pre-randomization) that is ≥ 6 (total score)as determined by the investigator.\n4. Visual Analog Scale (VAS) Symptom Index-Eye Dryness\u002FEye Discomfort total score (pre-dose) that is ≥ 40 points at screening and at Day 0 (pre-randomization).\n5. Willingness to have both the right and left eyes treated in the study.\n6. Willingness to discontinue contact lenses and all current DED treatments except artificial tears.\n7. Be able to demonstrate ability to use study medication bottle; this can be documented on study bottle used during washout period.\n8. Female subjects must be either: (1) of non-childbearing potential; or, (2) of childbearing potential and using an acceptable method of birth control with a negative pregnancy test :\n\n   1. Females of Non-childbearing Potential: Surgically sterilized (e.g., hysterectomy or bilateral oophorectomy) prior to screening; or, post-menopausal (i.e., no menstrual bleeding for at least 1 year prior to screening; or with a negative pregnancy test if less than 1 year post-menopausal).\n   2. Females of Childbearing Potential: Must agree to use a highly effective acceptable form of birth control (e.g., established hormonal birth control, or double barrier method: intrauterine device plus condom or spermicidal gel plus condom) from 21 days prior to dosing until 7 days after dosing.\n9. Providing written Informed Consent consistent with privacy language as per national regulations (e.g., HIPAA authorization) with signature obtained from the subject or legally authorized representative prior to the performance of any study related procedures (including withdrawal of prohibited medication.\n10. Willingness and ability to comply with schedule for follow-up visits and postoperative evaluations.\n\n    \\-\n\nExclusion Criteria:\n\n* Subjects who meet any of the following exclusion criteria for one or both eyes at screening will not be enrolled in the study. Subjects who meet any of the following exclusion criteria for one or both eyes on Day 0 will not be randomized and will be withdrawn from the study as screen failures:\n\n  1. Any abnormal lid anatomy or blinking function in either eye.\n  2. Using any topical ocular treatment other than the following medications:\n\n     a. Artificial Tears: Preservative-free artificial tears may be used as needed before and\u002For during the study. Whenever practicable, the same brand of artificial tears should be used throughout the study and its use documented in the patient diary throughout study participation.\n  3. Previous ocular surgery of any type (including lacrimal, corneal and trauma), except:\n\n     1. Non-refractive laser eye surgery of any type in either eye performed more than 3 months before screening is permitted.\n     2. Refractive surgery in either eye performed more than 6 months before screening is permitted.\n     3. Cataract surgery in either eye performed more than 3 months before screening is permitted\n  4. Any ocular anomaly that, in the investigator's opinion, interferes with the ocular surface, including:\n\n     1. Active ocular herpes simplex virus infection\n     2. Recurrent corneal erosion\n     3. Symptomatic epithelial basement membrane dystrophy\n     4. Mucus fishing syndrome\n     5. Giant papillary conjunctivitis\n     6. Post-radiation keratitis\n     7. Stevens-Johnson syndrome\n     8. Corneal ulcer\n     9. Abnormalities of the nasolacrimal drainage system\n     10. Chemical injury\n     11. Diagnosed significant anterior blepharitis and\u002For progressive pterygium\n  5. Current history of ocular infection (viral, bacterial, fungal), disease or inflammation (e.g., uveitis) not associated with dry eye, unless the disorder or disease is, in the investigator's opinion:\n\n     1. Stable for at least 3 months before the Screening Visit; and,\n     2. Not likely to impact or possibly interfere with the interpretation of study results.\n  6. Subjects with a current intraocular infection or with any other current eye or systemic condition (e.g., severe endothelial corneal dystrophy) that, in the investigator's opinion, would interfere with the dry eye evaluation or treatment, or for which the potential benefits of CAM-101 do not outweigh the risks.\n  7. History of ocular allergy (including seasonal conjunctivitis) or chronic conjunctivitis other than that secondary to dry eye.\n  8. Known hypersensitivity to the components of CAM-101 or the vehicle control (fibrinogen-depleted human platelet lysate; Plasma-Lyte A).\n  9. Known hypersensitivity to one of the procedural medications (e.g., proparacaine, fluorescein) unless a suitable alternative medication is available.\n  10. Inability to refrain from contact lens wear during the study, including the vehicle control run-in period.\n  11. Anticipated need for temporary or permanent punctum plugs during the study. (If punctum plugs have been in place for at least 4 weeks prior to the screening visit, the plugs are allowed to remain in place during the study. ) Patients must remain symptomatic for DED post punctal plug insertion.\n  12. Any ocular disease or ocular condition not stabilized within 1 month (30 days) before the screening visit.\n  13. Any clinically significant systemic disease or condition that is inadequately controlled (e.g., diabetes, thyroid disease, autoimmune disease) or not stabilized within 4 weeks before the screening visit.\n  14. Inability or unwillingness to discontinue use of autologous serum eye drops or platelet rich plasma eye drops during the 2-week run-in period and throughout the remainder of the study.\n  15. Female subjects who are pregnant or lactating or plan to become pregnant during the course of the study.\n  16. Subjects not under legal guardianship who, in the investigator's opinion, lack the mental capacity to provide written informed consent for study participation.",{"count":274,"type":21},475,[52],"Prospective, multicenter, randomized, vehicle-controlled, double-masked, study of CAM-101 topical ophthalmic solution compared to vehicle control followed by crossover to long-term follow-up open-label treatment with CAM-101 for one year.",[252,25,278,279],"Dry Eyes Chronic","Dry Eye Syndromes","2026-06-11",{"date":282,"type":30},"2026-06-12",{"date":284,"type":21},"2026-10-01",{"date":210,"type":21},{"name":287,"class":62},"Cambium Bio Limited",{"id":289,"slug":290,"hasResults":12,"nctId":291,"briefTitle":292,"officialTitle":293,"acronym":4,"eligibilityCriteria":294,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":295,"targetDuration":4,"studyType":50,"phases":297,"briefSummary":298,"conditions":299,"keywords":300,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":311,"locationsCount":4},"100638044","phase-2-a-phase-2-study-of-rci001-ophthalmic-solution-in-participants-with-dry-eye-disease-100638044","NCT07625124","A Phase 2 Study of RCI001 Ophthalmic Solution in Participants With Dry Eye Disease","A Phase 2, Multi-center, Randomized, Double-Masked and Placebo-Controlled Study Evaluating the Efficacy and Safety of RCI001 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye","Inclusion Criteria:\n\n1. At least 18 years of age at the Screening Visit (Visit 1), of either gender and any race.\n2. Able and willing to provide written informed consent.\n3. Willing and able to comply with all study procedures.\n4. Patient-reported history of dry eye for at least 6 months prior to Visit 1.\n5. History of use or desire to use eye drops for dry eye symptoms within 6 months of Visit 1.\n6. Best corrected visual acuity (BCVA) of 0.7 logMAR or better (Snellen equivalent of 20\u002F100 or better) in each eye at Visit 1.\n7. At least one eye, the same eye, must satisfy all criteria for Schirmer's Test, corneal fluorescein staining, conjunctival lissamine green staining, conjunctival redness, and CAE response.\n8. Female participants of childbearing potential must have a negative urine pregnancy test and must use adequate birth control throughout the study period. For non-sexually active females, abstinence may be regarded as an adequate method of birth control.\n\nExclusion Criteria:\n\n1. Clinically significant slit-lamp findings at Visit 1, including active blepharitis, meibomian gland dysfunction, severe lid margin inflammation, or active ocular allergies requiring therapeutic treatment, and\u002For findings that in the opinion of the investigator may interfere with study parameters. Participants with moderate to severe meibomian gland dysfunction, in the opinion of the investigator, are not eligible.\n2. Ongoing ocular infection, including bacterial, viral, or fungal infection, or active ocular inflammation at Visit 1.\n3. Contact lens wear within 7 days of Visit 1 or anticipated use of contact lenses during the study.\n4. LASIK surgery within the last 12 months.\n5. Female participant who is pregnant, nursing, or planning a pregnancy.\n6. Female participant of childbearing potential who is unwilling to submit a urine pregnancy test at Visit 1 and Visit 4, or at an early termination visit.\n7. Female participant of childbearing potential who is not using an acceptable method of birth control. Acceptable methods include hormonal contraceptives, mechanical contraception with spermicide and a barrier method, intrauterine device, or surgical sterilization of partner. For non-sexually active females, abstinence may be regarded as adequate; however, if the participant becomes sexually active during the study, she must agree to use adequate birth control for the remainder of the study.\n8. Known allergy and\u002For sensitivity to the test article or its components.\n9. Any condition or situation that, in the investigator's opinion, may put the participant at significant risk, may confound study results, or may interfere significantly with participation in the study.\n10. Current enrollment in an investigational drug or device study or use of an investigational drug or device within 30 days of Visit 1.\n11. Unable or unwilling to follow instructions, including participation in all study assessments and visits.",{"count":296,"type":21},200,[126],"This is a Phase 2 clinical study designed to evaluate the safety and efficacy of 0.25% RCI001 Ophthalmic Solution compared with placebo in participants with dry eye disease.\n\nThe study will enroll adults with dry eye disease. After a 2-week run-in period with placebo ophthalmic solution, eligible participants will be randomly assigned to receive either 0.25% RCI001 Ophthalmic Solution or placebo ophthalmic solution in both eyes for 4 weeks. Study treatment will be administered either twice daily or four times daily, depending on the assigned dosing regimen.\n\nThe main purpose of the study is to determine whether RCI001 improves the signs and symptoms of dry eye disease compared with placebo. The primary assessments include total corneal fluorescein staining and ocular discomfort at Day 28. Safety will be assessed through eye examinations, visual acuity, intraocular pressure, drop comfort, and adverse event monitoring.",[25],[301,302,303],"RCI001","Phase 2","Rudacure","2026-06-01",{"date":306,"type":30},"2026-06-04",{"date":308,"type":21},"2027-09-01",{"date":310,"type":21},"2028-08-30",{"name":303,"class":62},{"id":313,"slug":314,"hasResults":12,"nctId":315,"briefTitle":316,"officialTitle":316,"acronym":317,"eligibilityCriteria":318,"healthyVolunteers":97,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":319,"targetDuration":4,"studyType":50,"phases":321,"briefSummary":322,"conditions":323,"keywords":325,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":329,"startDateStruct":330,"completionDateStruct":332,"leadSponsor":334,"locationsCount":38},"100639590","the-effect-of-rinsing-on-ocular-inflammation-and-symptoms-in-patients-with-dry-eye-disease-100639590","NCT07618364","The Effect of Rinsing on Ocular Inflammation and Symptoms in Patients With Dry Eye Disease","RINSE-A","Inclusion Criteria:\n\n* MMP-9 Positivity in both eyes\n\nExclusion Criteria:\n\n* Active ocular infection, including bacterial, viral, or fungal conjunctivitis Acute allergic conjunctivitis or severe seasonal ocular allergy flare History of autoimmune ocular surface disease (e.g., Sjögren syndrome, ocular cicatricial pemphigoid, Stevens-Johnson syndrome) Current use of topical anti-inflammatory medications, including corticosteroids, cyclosporine, lifitegrast, or topical NSAIDs within 14-30 days prior to enrollment Initiation of new ocular or systemic anti-inflammatory therapy during the study period Contact lens wear within 12-24 hours prior to testing Ocular surgery or laser procedures within the previous 3-6 months Current punctal plug use or punctal occlusion procedures within the prior 3 months Severe aqueous-deficient dry eye preventing adequate tear sample acquisition or reliable InflammaDry testing Use of preserved artificial tears within a specified washout period Eyelid abnormalities or active blepharitis requiring treatment Pregnancy or breastfeeding (optional depending on IRB requirements) History of hypersensitivity to saline irrigation or study materials Any systemic inflammatory disease judged by investigators to confound tear film MMP-9 level",{"count":320,"type":21},33,[102],"The central hypothesis is that inflammation contributes to dry eye and that rinsing the palpebral conjunctiva, bulbar conjunctiva, and fornices will reduce the inflammatory burden on the ocular surface.",[279,25,324],"Ocular Surface Disease",[326,327],"ophthalmology","optometry","2026-05-26",{"date":304,"type":30},{"date":331,"type":30},"2022-01-01",{"date":333,"type":21},"2027-12-01",{"name":335,"class":62},"Rinsada",{"id":337,"slug":338,"hasResults":12,"nctId":339,"briefTitle":340,"officialTitle":340,"acronym":4,"eligibilityCriteria":341,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":342,"enrollmentInfo":343,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":345,"conditions":346,"keywords":4,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":347,"startDateStruct":349,"completionDateStruct":350,"leadSponsor":352,"locationsCount":4},"100638951","development-and-evaluation-of-an-intelligent-diagnosis-system-for-dry-eye-disease-based-on-confocal-microscopy-100638951","NCT07614347","Development and Evaluation of an Intelligent Diagnosis System for Dry Eye Disease Based on Confocal Microscopy","Inclusion Criteria:\n\nNormal group:\n\n1. Healthy adults aged 18 to 60;\n2. OSDI score of ocular surface disease Index \\\u003C13 points;\n3. Good tear film stability (tear film break-up time TBUT≥10 seconds) and negative corneal fluorescein staining;\n\nDry eye Group:\n\n1. Healthy adults aged 18 to 60;\n2. Tear film break-up time ≤5 seconds or SchirmerⅠ≤5mm\u002F5min without surface anesthesia, with one of the subjective symptoms such as dryness, foreign body sensation, burning sensation, fatigue, discomfort, or vision fluctuation in the eyes;\n3. 5 \\\u003CTear film break-up time ≤10 seconds or 5mm\u002F5 min\u002Fless under no surface anesthesia; When SchirmerⅠ is ≤10 mm\u002F5min, there is one of the subjective symptoms in the eyes, such as dryness, foreign body sensation, burning sensation, fatigue, discomfort, and vision fluctuation. At the same time, the fluorescein staining of the cornea and conjunctiva is positive.\n\nExclusion Criteria:\n\n1. Combined with systemic diseases or neurological diseases that may affect corneal nerve function;\n2. Having used any local anti-inflammatory drugs for the eyes within 2 weeks before enrollment or having a history of wearing contact lenses within 3 months;\n3. Other eye diseases besides dry eye and history of eye surgery;","60 Years",{"count":344,"type":21},75,"Dry eye disease is a major ophthalmic health issue that severely affects the visual function and quality of life of the national population. Its core pathological mechanism involves a vicious cycle of ocular surface inflammation and neural abnormalities; however, clinical practice still lacks an objective and quantitative gold standard for diagnosis. Although in vivo confocal microscopy (IVCM) enables cellular-level, in vivo observation of the ocular surface, image analysis remains heavily dependent on manual interpretation, highlighting an urgent need for an intelligent quantitative framework.This project aims to construct a high-quality, standardized ocular surface imaging database and develop a high-precision deep learning algorithm to achieve accurate segmentation and quantification of corneal nerves (including both whorl-like and linear patterns) and inflammatory cells, and to validate their associations with clinical indicators of dry eye disease. The ultimate goal is to develop and evaluate an IVCM-based multimodal intelligent diagnostic system for dry eye, transforming IVCM from an observational tool into an intelligent decision-support system, with real-world performance validated through an independent prospective cohort.This project is expected to establish a multimodal AI diagnostic model for dry eye, create a standardized computational framework for imaging biomarkers, and enable a paradigm shift from qualitative description to quantitative diagnosis. The findings will provide reliable decision-making support for precision subtyping and personalized treatment of dry eye disease, advancing ophthalmic practice toward a data-driven, intelligent paradigm.",[25],{"date":348,"type":30},"2026-05-29",{"date":304,"type":21},{"date":351,"type":21},"2028-12-31",{"name":353,"class":37},"Capital Medical University",{"id":355,"slug":356,"hasResults":12,"nctId":357,"briefTitle":358,"officialTitle":359,"acronym":4,"eligibilityCriteria":360,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":361,"targetDuration":4,"studyType":50,"phases":363,"briefSummary":364,"conditions":365,"keywords":367,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":377,"lastUpdatePostDateStruct":378,"startDateStruct":380,"completionDateStruct":382,"leadSponsor":383,"locationsCount":38},"100638090","phase-4-ocular-surface-health-and-tear-film-stability-with-a-nasal-spray-dry-eye-treatment-100638090","NCT07606625","Ocular Surface Health and Tear Film Stability With a Nasal Spray Dry Eye Treatment","The Impact of Varenicline Nasal Spray 0.03mg Dry Eye Treatment on Ocular Surface Health, Tear Film Stability, and Ocular Discomfort","Inclusion Criteria:\n\n* Is 18 years of age and has full legal capacity to volunteer (no max age requirement)\n* Baseline Ocular Surface Disease Index (OSDI) \\>13\n* Has mild to moderate MGD\n* Has best corrected visual acuity of 20\u002F40 or better\n* Has had an oculo-visual examination in the last two years\n* Is willing to continue other daily dry eye management regimen (e.g., warm compresses, and\u002For eyelid margin cleaning)\n* Is willing to discontinue other prescription medications for dry eye disease (DED) management\n* Is willing to stop any topical eye drops before all planned visits\n* Has read, understood, and completed the informed consent letter\n\nExclusion Criteria:\n\n* Is participating in any other type of clinical or research study\n* Is currently pregnant, nursing, lactating, or planning a pregnancy\n* Is currently having \\>50% blockage of Meibomian glands in more than two eyelids or significant atrophy (i.e., severe MGD)\n* Is currently using any topical ocular medications\n* Has chronic or currently active sinus related problems\n* Has blepharitis \\> grade 1\n* Has active ocular infections\n* Has a condition or in a situation which, in the examiner's opinion, may put the subject at significant risk, may confound the study results, or may significantly interfere with their participation in the study\n* Has received Rx DED treatment within one week of enrollment\n* Has received any thermal or light-based DED treatment within 30 days of enrollment\n* Has significant corneal epithelial defects\n* Has abnormal eyelid anatomy\n* Has corneal neuropathic pain\n* Has chronic or recurrent epistaxis (nosebleeds), coagulation disorders, or other conditions that may have led to a clinically significant increased risk of bleeding\n* Has any intraocular surgery including trabeculectomy (MIGS, laser, or small incision glaucoma surgery allowed), extraocular surgery in either eye within 3 months, or refractive surgery within 12 months of enrollment\n* Has a known allergy to a product used in this study",{"count":362,"type":21},65,[176],"The purpose of this study is to examine the impact of nasal spray treatment on Meibomian gland function and ocular surface health in symptomatic dry eye patients with mild to moderate Meibomian gland dysfunction (MGD).",[25,366],"Meibomian Gland Dysfunction",[368,369,370,371,372,373,374,375,376],"Dry eye disease","Meibomian gland dysfunction","Varenicline","Nasal spray dry eye treatment","Tear lipid layer","Tear thinning","Tear production","Tear film stability","Ocular discomfort","2026-05-22",{"date":379,"type":30},"2026-05-27",{"date":381,"type":30},"2026-03-06",{"date":164,"type":21},{"name":384,"class":37},"University of California, Berkeley",{"id":386,"slug":387,"hasResults":12,"nctId":388,"briefTitle":389,"officialTitle":390,"acronym":4,"eligibilityCriteria":391,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":392,"targetDuration":4,"studyType":50,"phases":394,"briefSummary":390,"conditions":395,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":396,"lastUpdatePostDateStruct":397,"startDateStruct":399,"completionDateStruct":401,"leadSponsor":403,"locationsCount":405},"100640384","a-study-to-evaluate-the-performance-and-safety-of-artelac-complete-mdo-versus-vismed-multi-eye-drops-in-the-management-of-moderate-to-severe-dry-eye-disease-100640384","NCT07593885","A Study to Evaluate the Performance and Safety of Artelac® Complete MDO® Versus VISMED® MULTI Eye Drops in the Management of Moderate to Severe Dry Eye Disease","A Double-Masked, Randomized, Parallel Group, Non-Inferiority Study to Evaluate the Performance and Safety of Artelac® Complete MDO® Versus VISMED® MULTI Eye Drops in the Management of Moderate to Severe Dry Eye Disease","Inclusion Criteria:\n\n1. Subject must be of legal age (at least 18) on the date the Informed Consent Form (ICF) is signed and must be able to read, understand, and provide written voluntary informed consent on the Ethics Committee (EC) approved ICF.\n2. Subject who is able and willing to comply with all treatment and follow-up\u002Fstudy procedures.\n3. Subject who have a history of using tear substitutes for at least 1 month prior to Visit 0 (Screening), and who will use preservative-free tear substitute (Artelac® Splash MDO®) at least 3 times a day for at least 10 days (± 3 days) immediately prior to randomization. All previously used tear substitutes will be discontinued at Visit 0 (Screening).\n4. Subject with dry eye disease (DED) secondary to Sjögren's disease with clear functional disorders or subjects with epidermolysis bullosa, or ocular pemphigoid, absence or damage to the lacrimal gland, facial paralysis or lagophthalmos requiring use of tear substitutes.\n5. Have a total OSDI score ≥ 23 at Visit 0 (Screening) and Visit 1 (Randomization)\n6. Subject with at least 1 eye with the following signs of moderate to severe DED:\n\n   1. TFBUT of \\\u003C 10sec (mean of 2 measurements) at both Visit 0 (Screening) and Visit 1 (Randomization).\n   2. Total ocular surface staining score ≥ 4 at both Visit 0 (Screening) and Visit 1 (Randomization). This assessment combines corneal, nasal, and temporal bulbar conjunctival fluorescein staining, each graded 0-5 according to the Oxford Scheme.\n7. If the subject is female, must fall into 1 of the following categories:\n\n   a. Post-menopausal (12 months after last menses) b. Surgically sterile c. Using one of the following birth control methods throughout the duration of the study: i. Intrauterine device (inserted at least 14 days prior to Visit 0 \\[Screening\\]) ii. Barrier method (condom or diaphragm) with spermicide (at least 14 days prior to Visit 0 \\[Screening\\]) iii. Hormonal contraception (stable dose and formulation for at least 6 months prior to Visit 0 \\[Screening\\]) iv. Abstinence (if this is in alignment with the lifestyle of the subject) Female subject who are of childbearing potential (i.e., who are not post-menopausal or not surgically sterile), must have a negative urine pregnancy test result at Visit 0 (Screening).\n\nExclusion Criteria:\n\nOcular Exclusion Criteria\n\n1. Subject who has received ocular surgery, including laser surgery, intraocular injections in either eye within 90 days prior to study start.\n2. Subject with acute ocular trauma, acute (non-dry eye) ocular inflammation, or acute ocular infection in either eye within 45 days prior to study start.\n\n   Treatment Exclusion Criteria\n3. Subject with known hypersensitivity or contraindications to any of the ingredients in the study or comparator products or ART, (especially, hyaluronic acid, glycerol, Myritol and carbomer)\n4. Subject with initiation of, or changes to, concomitant treatments that could affect dry eye within 30 days prior to Visit 0 (Screening) or with planned initiation, changes of such treatments during the study unless the investigator considers it clinically irrelevant.\n5. Subject with initiation of, or changes to topical glucocorticoid and doxycycline treatments that could affect dry eye within 30 days prior to Visit 0 (Screening) or with planned initiation or changes of such medications during the study unless the investigator considers it clinically irrelevant.\n6. Subject with initiation of, or changes to, topical cyclosporine that could affect dry eye within 90 days prior to Visit 0 (Screening), or with planned initiation or changes of such medications during the study\n7. Subject that is using or used serum or plasma derived eye drops within three months before start of screening.\n8. Subject have used an investigational drug or device within 30 days of Visit 0 (Screening) or be concurrently enrolled in another investigational drug or device study.\n9. Subject has previously been randomized in the present Study BL-CO04-ARTLCOMP-1401.\n10. The subject has a condition or is in a situation that, in the Investigator's opinion, may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study.\n11. Vulnerable subject who is unable to fully understand all aspects of the investigation that are relevant to the decision to participate, or who could be manipulated or unduly influenced as a result of a compromised position, expectation of benefits or fear of retaliatory response.",{"count":393,"type":21},160,[102],[25],"2026-05-12",{"date":398,"type":30},"2026-05-18",{"date":400,"type":30},"2026-04-30",{"date":402,"type":21},"2026-11",{"name":404,"class":62},"Dr. Gerhard Mann chem.-pharm. Fabrik GmbH",5,{"id":407,"slug":408,"hasResults":12,"nctId":409,"briefTitle":410,"officialTitle":411,"acronym":412,"eligibilityCriteria":413,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":414,"enrollmentInfo":415,"targetDuration":4,"studyType":50,"phases":416,"briefSummary":417,"conditions":418,"keywords":4,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":419,"lastUpdatePostDateStruct":420,"startDateStruct":421,"completionDateStruct":422,"leadSponsor":424,"locationsCount":4},"100624876","lacrima-vr-for-dry-eye-disease-and-meibomian-gland-dysfunction-100624876","NCT07415330","Lacrima VR for Dry Eye Disease and Meibomian Gland Dysfunction","A Randomized, Masked (Evaluator), Sham-Controlled, Prospective Study to Evaluate the Safety and Effectiveness of the Lacrima VR System in Subjects With Dry Eye Disease and Meibomian Gland Dysfunction","CLN-0154","Inclusion Criteria:\n\n* Adults aged 18 years and older\n* Ability to provide written informed consent\n* Willingness and ability to comply with study procedures and visits\n* Self-reported dry eye symptoms for at least 3 months\n* OSDI score ≥ 23 at baseline\n* Tear Break-Up Time (TBUT) \\\u003C 10 seconds in both eyes\n\nExclusion Criteria:\n\n* Ocular surgery within 1 year prior to screening\n* Active ocular infection or inflammation\n* History of ocular herpes infection within the past 3 months\n* Use of contact lenses within 3 months prior to screening or during the study\n* Use of prohibited dry eye or MGD treatments within protocol-defined washout periods\n* Diagnosis of epilepsy\n* Intraocular pressure \\> 20 mmHg\n* Pregnancy or breastfeeding","120 Years",{"count":124,"type":21},[102],"This is a prospective, multi-center, randomized, sham-controlled clinical investigation designed to evaluate the safety and effectiveness of the Lacrima VR system in adult subjects with Dry Eye Disease (DED) and Meibomian Gland Dysfunction (MGD). Subjects will be randomized in a 1:1 ratio to receive either active Lacrima VR treatment or a sham device with reduced luminance. Effectiveness will be assessed primarily by change in Tear Break-Up Time (TBUT), and safety will be evaluated by the incidence of device-related adverse events.",[25,279],"2026-05-11",{"date":396,"type":30},{"date":160,"type":21},{"date":423,"type":21},"2026-09-01",{"name":425,"class":62},"Demaod Ltd",{"id":427,"slug":428,"hasResults":12,"nctId":429,"briefTitle":430,"officialTitle":431,"acronym":432,"eligibilityCriteria":433,"healthyVolunteers":12,"sex":17,"minAge":434,"maxAge":435,"enrollmentInfo":436,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":438,"conditions":439,"keywords":440,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":445,"lastUpdatePostDateStruct":446,"startDateStruct":447,"completionDateStruct":449,"leadSponsor":451,"locationsCount":38},"100639027","evaluation-of-the-effectiveness-of-three-tear-substitute-formulations-in-postoperative-discomfort-after-cataract-surgery-100639027","NCT07581548","Evaluation of the Effectiveness of Three Tear Substitute Formulations in Postoperative Discomfort After Cataract Surgery","Evaluation of the Effectiveness of Three Tear Substitute Formulations in Postoperative Discomfort After Cataract Surgery: A Non- Interventional, Observational Study","DRY-CAT","Inclusion Criteria:\n\nDiagnosis of senile cataract with stage 2 or 3 nuclear opalescence according to the - Lens Opacities Classification System III (LOCS-3) grading scale\n\nExclusion Criteria:\n\n1. Former incisional surgery\n2. Former diagnosis of corneal disease\n3. Autoimmune diseases\n4. Mental diseases","45 Years","85 Years",{"count":437,"type":21},300,"The primary objective of this study is the assessment of three tear substitute formulations in terms of postoperative discomfort following cataract extraction surgery by means of phacoemulsification and intraocular lens implantation.",[250,25],[441,442,443,444],"dry eye","cataract surgery","sodium hyaluronate","artificial tears","2026-05-06",{"date":396,"type":30},{"date":448,"type":21},"2026-05-01",{"date":450,"type":21},"2027-05-01",{"name":452,"class":37},"Democritus University of Thrace",{"id":454,"slug":455,"hasResults":12,"nctId":456,"briefTitle":457,"officialTitle":458,"acronym":4,"eligibilityCriteria":459,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":460,"enrollmentInfo":461,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":462,"conditions":463,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":445,"lastUpdatePostDateStruct":464,"startDateStruct":465,"completionDateStruct":467,"leadSponsor":469,"locationsCount":38},"100638242","comparative-assessment-of-lipid-layer-thickness-measurements-100638242","NCT07579130","Comparative Assessment of Lipid Layer Thickness Measurements","Comparative Assessment of Lipid Layer Thickness Measurements Across Three Devices and Their Correlation With Clinical Indicators in Dry Eye Disease","Inclusion Criteria:\n\n* Dry eye disease\n\nExclusion Criteria:\n\n* None","100 Years",{"count":100,"type":21},"This study compares ocular lipid layer thickness (LLT) measurements obtained from three commonly used clinical diagnostic devices to evaluate their agreement and consistency. It further examines which device's LLT measurements show the strongest correlation with established clinical indicators of dry eye disease severity.",[25],{"date":419,"type":30},{"date":466,"type":30},"2026-04-01",{"date":468,"type":21},"2028-12-20",{"name":470,"class":37},"Indiana University",{"id":472,"slug":473,"hasResults":12,"nctId":474,"briefTitle":475,"officialTitle":475,"acronym":4,"eligibilityCriteria":476,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":477,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":478,"conditions":479,"keywords":480,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":482,"lastUpdatePostDateStruct":483,"startDateStruct":485,"completionDateStruct":487,"leadSponsor":489,"locationsCount":38},"100636537","real-world-assessment-of-vevye-for-short-term-symptom-and-sign-improvement-of-dry-eye-disease-in-a-neuro-ophthalmology-clinic-a-6-month-prospective-observational-study-100636537","NCT07566975","Real-World Assessment of VEVYE® for Short-Term Symptom and Sign Improvement of Dry Eye Disease in a Neuro-Ophthalmology Clinic: A 6-Month Prospective Observational Study","Inclusion Criteria:\n\n* Age18 yr or older Diagnosis of neuro-ophthalmic condition Clinical diagnosis of dry eye disease OSDI score of 23 or greater at baseline Objective sign present Indicated for VEVYE prior to enrollment Ability and willingness to complete study visits and questionnaires\n\nExclusion Criteria:\n\n* Patients with a corneal ulcer Use of another cyclosporine or lifitegrast product within 30 days of baseline Ocular surgery within 30 prior to baseline Active ocular infection or severe ocular surface condition unrelated to DED Contact lens wearers ( must be off contacts for 30 days and the duration of trial) Any condition that prevents compliance or informed consent Subjects with severe scarring \u002F zero sensitivity",{"count":100,"type":21},"patients from a Neuro Ophthalmology who have dry eye, some of which have neurotrophic keratitis are being analyzed after treatment with Vevye",[25],[481,25],"Neurotrophic Keratitis","2026-04-28",{"date":484,"type":30},"2026-05-05",{"date":486,"type":30},"2026-03-31",{"date":488,"type":21},"2026-11-30",{"name":490,"class":37},"Neuro-Ophthalmology of Texas",{"id":492,"slug":493,"hasResults":12,"nctId":494,"briefTitle":495,"officialTitle":495,"acronym":4,"eligibilityCriteria":496,"healthyVolunteers":97,"sex":17,"minAge":497,"maxAge":98,"enrollmentInfo":498,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":499,"conditions":500,"keywords":501,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":502,"lastUpdatePostDateStruct":503,"startDateStruct":504,"completionDateStruct":506,"leadSponsor":508,"locationsCount":38},"100635609","detection-and-optimization-of-treatment-of-severe-cases-of-dry-eye-disease-100635609","NCT07554911","Detection and Optimization of Treatment of Severe Cases of Dry Eye Disease","Inclusion Criteria:\n\n1. 21 years old and above\n2. Participants must be previously diagnosed with dry eye in the dry eye clinic (previous referred and had various forms of treatment such as artificial tears or prescription eyedrops)\n3. Willing to perform all eye examinations and questionnaires in this study\n4. Ability to provide informed consent\n\nExclusion Criteria:\n\n1. All subjects meeting any of the exclusion criteria at baseline will be excluded from participation and then list the criterion.\n2. Any other specified reason as determined by clinical investigator","21 Years",{"count":296,"type":21},"The bulk of dry eye patients are found in the community. The lack of satisfactory protocols and confidence is a significant deterrent for practitioners to manage such patients, which may result in inaccurate referrals, and unhappy patients. Problems are compounded by comorbidities of dry eye, even if these are not diagnosed formally.\n\nAligning with the healthcare strategy to move beyond healthcare to health, and beyond hospital care to community care, investigators propose that the confidence of primary carers be increased by using an image-based screening system.\n\nThis study aim to determine the efficacy of this screening AI algorithm, a prototype, in addition to or instead of screening of dry eye using a simple DEQ-5 symptom questionnaire.",[25],[441],"2026-04-27",{"date":448,"type":30},{"date":505,"type":30},"2023-10-18",{"date":507,"type":21},"2028-07-31",{"name":509,"class":510},"Singapore National Eye Centre","OTHER_GOV",{"id":512,"slug":513,"hasResults":12,"nctId":514,"briefTitle":515,"officialTitle":516,"acronym":517,"eligibilityCriteria":518,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":519,"targetDuration":4,"studyType":50,"phases":521,"briefSummary":522,"conditions":523,"keywords":4,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":524,"lastUpdatePostDateStruct":525,"startDateStruct":526,"completionDateStruct":528,"leadSponsor":529,"locationsCount":38},"100636057","phase-4-clinical-evaluation-of-lifitegrast-ophthalmic-solution-50-in-dry-eye-disease-using-in-vivo-confocal-microscopy-100636057","NCT07560735","Clinical Evaluation of Lifitegrast Ophthalmic Solution 5.0% in Dry Eye Disease Using In Vivo Confocal Microscopy","Clinical Evaluation of Lifitegrast Ophthalmic Solution 5.0% in Dry Eye Disease Using In Vivo Confocal Microscopy (IVCM)","(IVCM)","Inclusion Criteria:\n\n* 1\\. Subject can read, understand and sign an informed consent letter. 2. Provision of signed and dated informed consent form and HIPAA authorization. 3. Stated willingness to comply with all study procedures and availability for the duration of the study 4. Male or female at least 18 years of age at the time of enrollment 5. Minimum corneal staining of ≥2 or greater according to the NEI grading scale in the lower corneal subregion.\n\nNormal eyelids and corneal anatomy 7. For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional 4 weeks after the end of study drug administration 8.\n\nFor males of reproductive potential: should be able to agree to use at least 1 medically acceptable form of birth control with female partner (FOCBP) NOTE: Acceptable forms of birth control include:\n\n• True abstinence (when this is in line with the preferred and usual lifestyle of the subject), or\n\n• Vasectomy at least 3 months prior to the first dose of study drug\n\n• Without a vasectomy, must use condoms with spermicidal foam, gel, film, cream, suppository at least 14 days prior to the first dose of investigational drug and throughout the study duration, and for 4 weeks after the last dose of the investigational drug.\n\n• Or the female partner of the male investigational subject, must comply with the previous points.\n\n9\\. Are postmenopausal (no menstrual cycle for at least one year prior to Visit 1) or have undergone bilateral tubal ligation, hysterectomy, hysterectomy with uni- or bilateral oophorectomy, or bilateral oophorectomy for 1 year prior to study start.\n\n10\\. Best corrected visual acuity of 0.7 logMAR or better (Snellen equivalent score of 20\u002F100 or better) in each eye at day -14 (Visit 1) and Day 0 (Visit 2) 11. Subject-reported history of dry eye for at least 6 months. 12. Schirmer Tear Test (without anesthesia) ≥1mm and ≤10mm at baseline 13. EDS score of ≥40 (0-100-point VAS, both eyes) value is an average at screening and baseline.\n\nExclusion Criteria:\n\n* 1\\. Have a known hypersensitivity or contraindication to the product or their components.\n\nUnwilling to discontinue contact lens use for the duration of the study 3. Pregnancy or lactation 4. Have used topical or nasal vasoconstrictors within 14 days prior to screening or unable to refrain from the same during study period 5. Subjects that use topical steroids, systemic immunosuppressive agents including oral corticosteroids, antihistamines, mast cell stabilizers or glaucoma medications.\n\n6\\. Subjects unwilling to abstain from eyelash growth products containing prostaglandins for the duration of the trial.\n\n7\\. Subjects who had ocular surgery within the past 1 year prior to Visit 1. 8. Febrile illness within one week. 9. Active or history of infectious keratitis; any other ocular infection within the last 30 days 10. Have serious or severe disease or uncontrolled medical condition that in the judgement of the investigator could confound study assessments or limit compliance.\n\n11\\. Use of new prescription eyedrop within 30 days of screening 12. Change in systemic medication within 30 days of screening 13. Any subject who has previously tried and failed a course of lifitegrast. 14. Subjects with secondary Sjogren's syndrome (ex. Rheumatoid arthritis, systemic lupus, erythematosus) or other autoimmune disease (ex: multiple sclerosis, inflammatory bowel disease) are eligible for enrollment consideration provided the subject met all other inclusion and exclusion criteria, AND, were not in a medical state in the opinion of the principle investigator that could have interfered with the study parameters, were not taking systemic\u002Focular steroids and were not immunodeficient\u002Fimmunosuppressed (ex: receiving systemic immunomodulating or immunosuppressive drugs to manage their baseline medical state.)",{"count":520,"type":21},30,[176],"This is a single center, open label trial to evaluate Lifitegrast Ophthalmic Solution 5.0% in Dry Eye Disease using In Vivo Confocal Microscopy (IVCM",[25],"2026-04-23",{"date":448,"type":30},{"date":527,"type":21},"2026-04",{"date":113,"type":21},{"name":530,"class":37},"Toyos Clinic",{"id":532,"slug":533,"hasResults":12,"nctId":534,"briefTitle":535,"officialTitle":536,"acronym":4,"eligibilityCriteria":537,"healthyVolunteers":97,"sex":17,"minAge":18,"maxAge":538,"enrollmentInfo":539,"targetDuration":4,"studyType":50,"phases":541,"briefSummary":543,"conditions":544,"keywords":4,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":545,"lastUpdatePostDateStruct":546,"startDateStruct":548,"completionDateStruct":549,"leadSponsor":551,"locationsCount":4},"100633058","phase-1-a-study-to-evaluate-the-safety-tolerability-and-pharmacokinetic-profile-of-rc017-ophthalmic-ointment-following-single-and-multiple-doses-in-healthy-adult-participants-100633058","NCT07521748","A Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of RC017 Ophthalmic Ointment Following Single and Multiple Doses in Healthy Adult Participants","A Single-Center, Randomized, Double-Blind, Placebo-Controlled Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of RC017 Ophthalmic Ointment Following Single and Multiple Doses in Healthy Adult Participants","Inclusion Criteria:\n\n1. Healthy male and female trial participants aged 18 to 55 years old (inclusive);\n2. Body Mass Index (BMI) ranging from 19.0 to 26.0 kg\u002Fm² (inclusive), with body weight ≥ 50 kg for males and ≥ 45 kg for females;\n3. At screening, best corrected visual acuity (BCVA) of both eyes should be ≥ 1.0; in addition, ophthalmic examinations (including assessment of ocular symptoms, slit-lamp microscopy\u002Fexternal eye examination, corneal fluorescein staining, funduscopy, and intraocular pressure measurement) should show no abnormalities in both eyes, or any abnormalities detected should be judged as clinically insignificant by the investigator;\n4. Have a full understanding of the trial procedures, voluntarily participate in the trial, and sign a written informed consent form (ICF);\n5. Female participants with childbearing potential must have a negative result in the serum pregnancy test at screening. Throughout the entire study period and within 3 months after the study conclusion, all female participants, male participants and their sexual partners must agree to adopt effective contraceptive measures (Note: Contraceptive measures include both pharmacological and non-pharmacological methods, see Appendix 4 for details).\n\nExclusion Criteria:\n\n1. History of ocular diseases deemed by the investigator as unsuitable for enrollment, including but not limited to dry eye, glaucoma, blepharitis, meibomianitis, allergic conjunctivitis, iritis, uveitis, and\u002For active ocular inflammation or infection.\n2. Prior history of ocular surgeries, including laser refractive surgery and intraocular surgery, etc.\n3. Participants who wore contact lenses or cosmetic colored contact lenses within 2 weeks prior to screening, or those requiring contact lens wear during the trial.\n4. Use of any prescription or over-the-counter (OTC) medications (including vitamins, antacids, Chinese herbal medicines, dietary supplements, and topical ophthalmic drugs) within 2 weeks prior to screening.\n5. Clinically significant abnormalities in vital signs, physical examination findings, laboratory test results (complete blood count \\[CBC\\], urine routine, blood biochemistry, coagulation function, infectious disease screening, serum pregnancy test \\[females only\\]) or 12-lead electrocardiogram (ECG), as judged by the investigator.\n6. History of diseases involving the central nervous, mental, cardiovascular, renal, hepatic, respiratory, metabolic, or musculoskeletal systems, which in the investigator's judgment may compromise participant safety or interfere with study results.\n7. Clinically significant history of allergies, especially drug allergies, or known hypersensitivity to any component of the study drug.\n8. Daily cigarette smoking \\> 5 sticks within 3 months prior to the trial.\n9. Suspected or confirmed alcohol dependence; average daily alcohol intake \\> 2 units within 3 months (1 unit = 10 mL pure ethanol, equivalent to 200 mL beer \\[5% alcohol\\], 25 mL spirits \\[40% alcohol\\], or 83 mL wine \\[12% alcohol\\]); or positive alcohol test result.\n10. History of drug abuse; or positive urine test for ketamine, morphine, methamphetamine, MDMA, or tetrahydrocannabinol carboxylic acid (THC-COOH).\n11. Participation in another clinical trial within 3 months prior to screening.\n12. Blood donation or blood loss ≥ 400 mL within 3 months prior to screening.\n13. Pregnant or lactating females.\n14. Unsuitability for venous blood collection.\n15. Vaccination within 30 days prior to screening, or planned vaccination during the study period.\n16. Any other conditions deemed by the investigator as unsuitable for enrollment.","55 Years",{"count":540,"type":21},24,[542],"PHASE1","This is a Single-Center, Randomized, Double-Blind, Placebo-Controlled Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of RC017 Ophthalmic Ointment Following Single and Multiple Doses in Healthy Adult Participants.RC017 is a small-molecule drug, being developed as a novel therapeutic treatment for patients with Dry Eye Disease (DED) . This study aims to evaluate the safety, tolerability and pharmacokinetics of RC017 after Single and Multiple Doses.",[25],"2026-04-07",{"date":547,"type":30},"2026-04-13",{"date":527,"type":21},{"date":550,"type":21},"2027-04",{"name":552,"class":62},"Nanjing Reju Therapeutics Co., Ltd",{"id":554,"slug":555,"hasResults":12,"nctId":556,"briefTitle":557,"officialTitle":558,"acronym":4,"eligibilityCriteria":559,"healthyVolunteers":12,"sex":17,"minAge":560,"maxAge":4,"enrollmentInfo":561,"targetDuration":4,"studyType":50,"phases":562,"briefSummary":563,"conditions":564,"keywords":565,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":466,"lastUpdatePostDateStruct":568,"startDateStruct":570,"completionDateStruct":572,"leadSponsor":573,"locationsCount":38},"100632202","phase-4-single-arm-study-of-a-treatment-for-dry-eye-in-people-who-struggle-to-wear-contact-lenses-100632202","NCT07510620","Single-Arm Study of a Treatment for Dry Eye in People Who Struggle to Wear Contact Lenses","Prospective, Single Arm Clinical Trial for the Treatment of Dry Eyes Signs and Symptoms in Patients With Limited Tolerability of Contact Lens Wear","Inclusion Criteria\n\n* \\>21 years of age\n* Contact lens wearer\n* Previous Dry Eye Treatment\n* Be on a stable dose of antihistamines\u002FBirth Control Medication and Lifitegrast and cyclosporine.\n* Schrimers Anesthetized less than or equal to 10\n* CLDEQ-8 greater than or equal to 12\n* Corneal Staining NEI grading scale greater than or equal to 1\n\nExclusion Criteria:\n\n* Known allergy to Hyaluronic Acid\n* Current topical ophthalmic drops other than dry eye treatment\n* Uncontrolled Diabetes\n* Diabetic Retinopathy\n* Pregnancy or Lactating\n* Corneal Surgery (except Refractive)\n* Corneal Scars\n* Keratoconus\n* Ocular Herpetic Keratitis","22 Years",{"count":520,"type":21},[176],"This research study is to see if using Lacrifill is safe, easy to use, and helpful for people who wear contact lenses but can't wear them comfortably for long. Specifically, the study aims to determine whether regular use of Lacrifill over a 2-3 month period can help people wear their contacts longer without discomfort and reduce signs and symptoms of dry eye.",[25],[25,566,567],"Lacrifill","contact lenses",{"date":569,"type":30},"2026-04-03",{"date":571,"type":30},"2025-12-12",{"date":84,"type":21},{"name":574,"class":37},"Vision Innovation Centers of Pennsylvania, LLC d\u002Fb\u002Fa Eye Care Specialists",{"id":576,"slug":577,"hasResults":12,"nctId":578,"briefTitle":579,"officialTitle":580,"acronym":581,"eligibilityCriteria":582,"healthyVolunteers":97,"sex":17,"minAge":18,"maxAge":583,"enrollmentInfo":584,"targetDuration":4,"studyType":50,"phases":585,"briefSummary":586,"conditions":587,"keywords":588,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":589,"lastUpdatePostDateStruct":590,"startDateStruct":592,"completionDateStruct":594,"leadSponsor":596,"locationsCount":38},"100631324","study-of-blinking-as-a-function-of-tear-film-quality-100631324","NCT07499193","Study of Blinking as a Function of Tear Film Quality","Etude Des Clignements en Fonction de la Qualité du Film Lacrymal","WINK","Inclusion Criteria:\n\n* Volunteer, fluent in French, willing to follow the protocol, able to read and understand the information sheet and provide free and informed consent\n* Covered by a social security\n* Aged between 18 and 65 years inclusive\n* Binocular near visual acuity ≤ 0.3 LogMAR (≥ 5\u002F10) (corrective glasses accepted)\n\nExclusion Criteria:\n\n* Employees of Essilor International, Luxottica, or GrandVision and their subsidiaries\n* Pregnant or breastfeeding women (Article L1121-5)\n* Individuals deprived of liberty by judicial or administrative decision, or hospitalized without consent under Articles L.3212-1 and L.3213-1, who do not fall under Article L.1121-8, and individuals admitted to a health or social care facility for purposes other than research\n* Adults unable or incapable of giving informed consent (Article L1121-8)\n* Participants currently in an exclusion period from another study\n* Participants deemed unfit to participate by the investigator for any reason that may affect subject safety or study integrity All categories of individuals particularly protected under French law are excluded from this research (Articles L1121-5 to L1121-9 of the French Public Health Code).\n* Use of eye drops or ophthalmic solutions within the last 2 hours\n* Wearing contact lenses within the last 48 hours\n* Reported history of severe ocular pathology such as glaucoma, retinitis pigmentosa, diabetic retinopathy, macular involvement, resulting in visual field loss or acuity loss (especially aphakia), except for dry eye (which is not an exclusion criterion)\n* Reported history of eye surgery or trauma to the eye or its adnexa excepted refractive surgery and cataract surgery\n* Reported history of eyelid abnormalities (ptosis)\n* Reported history of neurological deficits, including epilepsy or sensory-motor coordination disorders, vestibular or cerebellar pathology (e.g., balance disorders, nystagmus, Parkinson's disease)\n* Reported history of musculoskeletal disorders preventing maintenance of a fixed head position","65 Years",{"count":20,"type":21},[102],"The goal of this study is to better understand how eye blinking behavior is linked to the stability of the tear film, in adults aged 18 to 65 years, with or without symptoms of dry eye.\n\nThe main questions are:\n\n* Do the results of a New Blink Task reflect tear film stability ?\n* How are the blink related metrics in relation with each other? Researchers will compare two groups of participants-those without dry eye symptoms and those with dry eye symptoms-to see if blinking measures differ between them and whether these measures relate differently to tear film quality.\n\nParticipants will:\n\n* Answer a questionnaire about dry eye symptoms\n* Have their visual correction measured (if they wear glasses)\n* Undergo non-invasive assessments of tear film quality using an imaging device\n* Complete three types of blink tasks, each repeated three times, including measurements of blinking and of tear film stability",[25],[441],"2026-03-23",{"date":591,"type":30},"2026-03-30",{"date":593,"type":21},"2026-03",{"date":595,"type":21},"2026-06",{"name":597,"class":62},"Essilor International"]